hematologic malignancies Oct 28, 2022 Gilead Sciences' Oncology Sales Soar 79 Percent in Q3 Premium Oct 20, 2022 Kite Pharma Licenses Refuge Biotechnologies Platform to Bolster CAR T-Cell Therapy Development Oct 12, 2022 Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies Premium Sep 26, 2022 WEHI Launches Project to Improve Genomic Data Interpretation, Precision Cancer Care in Australia Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Aug 29, 2022 Novartis' Scemblix Nets European Approval for Subset of CML Patients Aug 25, 2022 VolitionRx Taking on Nucleosome-Focused Dx for Human Cancers After Canine Cancer Screening Test Premium Aug 10, 2022 Bristol Myers Squibb, 2seventy Bio Eyeing Earlier-Line Multiple Myeloma Abecma Indication Aug 1, 2022 OriCell Therapeutics Raises $120M in Series B Round Jun 28, 2022 European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients Jun 24, 2022 EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients May 20, 2022 FDA, Industry Look to Congress to Reauthorize User-Fee Act, Improve Cell Therapy Regulation Premium Apr 28, 2022 Owkin, ADC Therapeutics Team on AI-Based Biomarker Discovery Apr 4, 2022 FDA Approves Gilead's Yescarta as Second-Line Treatment for Large B-Cell Lymphoma Patients Mar 29, 2022 Thermo Fisher Scientific Obtains CE Mark for Ion Torrent Genexus Dx Integrated Sequencer Oct 22, 2021 Genetron Health, Fosun Ink Commercialization Deal for Seq-MRD Test in China Jul 30, 2021 Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent May 19, 2021 Icelandic Study Assessing Benefit of Population-Based Multiple Myeloma Risk Screening, Intervention Apr 19, 2021 Eden BioCell Doses First Patient in Phase I CAR T-Cell Study Mar 29, 2021 FDA Approves Bristol Myers Squibb, Bluebird Bio's Multiple Myeloma CAR T-Cell Therapy Abecma Load More Breaking News Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody
